<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Clinical Trials &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/clinical-trials/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 10 Nov 2025 23:51:19 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Clinical Trials &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>UCLA Researchers Secure Funding to Establish Cancer Research Center at VA</title>
		<link>https://bioengineer.org/ucla-researchers-secure-funding-to-establish-cancer-research-center-at-va/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 10 Nov 2025 23:51:15 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[İşte içeriğe uygun 5 etiket: **Precision oncology]]></category>
		<category><![CDATA[lung cancer research]]></category>
		<category><![CDATA[VA medical centers** **Kısa açıklama:** 1. **Precision oncology:** Metnin ana teması ve araştırmanın temel yaklaşımı. 2. **Veteran healthcare:** Fonun ve merkezin doğrudan hedef kitlesi ve odak n]]></category>
		<category><![CDATA[Veteran healthcare]]></category>
		<guid isPermaLink="false">https://bioengineer.org/ucla-researchers-secure-funding-to-establish-cancer-research-center-at-va/</guid>

					<description><![CDATA[In a landmark advancement for oncology research and veteran healthcare, Dr. Matthew Rettig and his team at UCLA have secured a prestigious Clinical Cancer Research Center grant from the U.S. Department of Veterans Affairs. This significant funding will establish a pioneering clinical cancer research infrastructure aimed at enhancing access to precision oncology clinical trials and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">294408</post-id>	</item>
		<item>
		<title>Faster Diagnostic Scans Could Revolutionize Prostate Cancer Detection for Millions</title>
		<link>https://bioengineer.org/faster-diagnostic-scans-could-revolutionize-prostate-cancer-detection-for-millions/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 10 Sep 2025 15:37:10 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Biparametric MRI]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Diagnostic imaging]]></category>
		<category><![CDATA[Healthcare efficiency]]></category>
		<category><![CDATA[Prostate cancer detection]]></category>
		<guid isPermaLink="false">https://bioengineer.org/faster-diagnostic-scans-could-revolutionize-prostate-cancer-detection-for-millions/</guid>

					<description><![CDATA[A groundbreaking clinical trial led by researchers from University College London (UCL), UCL Hospitals (UCLH), and the University of Birmingham has demonstrated that a significantly faster and more cost-effective MRI scan can diagnose prostate cancer with the same accuracy as the current standard procedure. This advancement has the potential to revolutionize prostate cancer diagnostics worldwide [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">268366</post-id>	</item>
		<item>
		<title>Oral Semaglutide Significantly Decreases Incidence of Heart Attacks and Strokes in Type 2 Diabetes Patients</title>
		<link>https://bioengineer.org/oral-semaglutide-significantly-decreases-incidence-of-heart-attacks-and-strokes-in-type-2-diabetes-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 29 Mar 2025 18:36:32 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cardiovascular outcomes]]></category>
		<category><![CDATA[cardiovascular risk reduction]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[GLP-1 receptor agonist]]></category>
		<category><![CDATA[heart attack prevention]]></category>
		<category><![CDATA[oral semaglutide]]></category>
		<category><![CDATA[stroke prevention]]></category>
		<category><![CDATA[Type 2 diabetes]]></category>
		<guid isPermaLink="false">https://bioengineer.org/oral-semaglutide-significantly-decreases-incidence-of-heart-attacks-and-strokes-in-type-2-diabetes-patients/</guid>

					<description><![CDATA[In recent years, the therapeutic landscape for type 2 diabetes has witnessed groundbreaking advancements, particularly with the introduction of medications like semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. This drug has gained significant attention for its remarkable efficacy not just in managing blood sugar levels but also in addressing weight gain and even alcohol cravings. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">239539</post-id>	</item>
		<item>
		<title>Immunotherapy Enhances Effectiveness of KRAS-Targeted Treatments in Pancreatic Cancer</title>
		<link>https://bioengineer.org/immunotherapy-enhances-effectiveness-of-kras-targeted-treatments-in-pancreatic-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 14 Mar 2025 18:31:03 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[immunotherapy combination]]></category>
		<category><![CDATA[KRAS-targeted therapies]]></category>
		<category><![CDATA[multi-selective inhibitors]]></category>
		<category><![CDATA[Pancreatic cancer treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/immunotherapy-enhances-effectiveness-of-kras-targeted-treatments-in-pancreatic-cancer/</guid>

					<description><![CDATA[In a groundbreaking study that has the potential to reshape the treatment landscape for pancreatic cancer, researchers from the Perelman School of Medicine at the University of Pennsylvania have demonstrated that the addition of immunotherapy to a novel class of multi-selective inhibitors targeting the notorious cancer-causing gene mutation, KRAS, can significantly improve treatment outcomes in [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">238452</post-id>	</item>
		<item>
		<title>Prehabilitation Demonstrates Potential for Enhancing Health and Minimizing Surgical Complications</title>
		<link>https://bioengineer.org/prehabilitation-demonstrates-potential-for-enhancing-health-and-minimizing-surgical-complications/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 23 Jan 2025 01:04:00 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[patient engagement]]></category>
		<category><![CDATA[postoperative recovery]]></category>
		<category><![CDATA[prehabilitation]]></category>
		<category><![CDATA[surgical outcomes]]></category>
		<guid isPermaLink="false">https://bioengineer.org/prehabilitation-demonstrates-potential-for-enhancing-health-and-minimizing-surgical-complications/</guid>

					<description><![CDATA[A groundbreaking study published in The BMJ has revealed that prehabilitation—a proactive approach aimed at enhancing a patient’s physical and mental condition before surgery—holds significant promise in improving surgical outcomes. The research, led by Dr. Daniel McIsaac, an anesthesiologist and senior scientist at The Ottawa Hospital, compiles data from over 15,000 patients involved in 186 [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">234572</post-id>	</item>
		<item>
		<title>Osimertinib Resistance and EGFR Mutations in NSCLC Treatment</title>
		<link>https://bioengineer.org/osimertinib-resistance-and-egfr-mutations-in-nsclc-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 16 Jan 2024 16:03:03 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[C797 mutation]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Drug resistance mechanisms]]></category>
		<category><![CDATA[EGFR mutations]]></category>
		<category><![CDATA[EGFR-TKI resistance]]></category>
		<category><![CDATA[Genomic analysis]]></category>
		<category><![CDATA[lung cancer]]></category>
		<category><![CDATA[Molecular oncology]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Osimertinib]]></category>
		<category><![CDATA[T790M mutation]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<category><![CDATA[TKI combinations]]></category>
		<category><![CDATA[Treatment strategies]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=219366</guid>

					<description><![CDATA[The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein&#8217;s ATP binding site, overcoming resistance mechanisms. Analysis of circulating tumor (ct) [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">219366</post-id>	</item>
		<item>
		<title>Phase II Clinical Study Results of the HERTHENA-Lung01 Study</title>
		<link>https://bioengineer.org/phase-ii-clinical-study-results-of-the-herthena-lung01-study/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Nov 2023 17:47:15 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer research]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[EGFR-mutant NSCLC]]></category>
		<category><![CDATA[HER3-DXd]]></category>
		<category><![CDATA[HER3-targeted therapy]]></category>
		<category><![CDATA[late-stage treatment]]></category>
		<category><![CDATA[lung cancer therapy.]]></category>
		<category><![CDATA[oncology innovations]]></category>
		<category><![CDATA[patritumab deruxtecan]]></category>
		<category><![CDATA[Phase II Clinical Trial Results of the HERTHENA-Lung01 Studylung cancer]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=217034</guid>

					<description><![CDATA[Lung cancer is one of the most common types of cancer worldwide, and the treatment process for patients with non-small cell lung cancer (NSCLC) carrying EGFR mutations can be particularly complex. This disease is characterized by uncontrolled growth and proliferation of cells in the lungs. The EGFR mutation is considered a significant factor in the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">217034</post-id>	</item>
		<item>
		<title>New organ-on-a-chip finds crucial interaction between blood, ovarian cancer tumors</title>
		<link>https://bioengineer.org/new-organ-on-a-chip-finds-crucial-interaction-between-blood-ovarian-cancer-tumors/</link>
					<comments>https://bioengineer.org/new-organ-on-a-chip-finds-crucial-interaction-between-blood-ovarian-cancer-tumors/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jul 2021 18:56:09 +0000</pubDate>
				<category><![CDATA[Science News]]></category>
		<category><![CDATA[Biomedical/Environmental/Chemical Engineering]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-organ-on-a-chip-finds-crucial-interaction-between-blood-ovarian-cancer-tumors/</guid>

					<description><![CDATA[Team identifies crucial interaction between platelets and tumors for the first time Credit: Texas A&#038;M Engineering In the evolving field of cancer biology and treatment, innovations in organ-on-a-chip microdevices allow researchers to discover more about the disease outside the human body. These organs-on-chips serve as a model of the state an actual cancer patient is [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/new-organ-on-a-chip-finds-crucial-interaction-between-blood-ovarian-cancer-tumors/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">174495</post-id>	</item>
		<item>
		<title>Advantages of intranasal vaccination against SARS-CoV-2</title>
		<link>https://bioengineer.org/advantages-of-intranasal-vaccination-against-sars-cov-2/</link>
					<comments>https://bioengineer.org/advantages-of-intranasal-vaccination-against-sars-cov-2/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jul 2021 17:40:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Immunology/Allergies/Asthma]]></category>
		<category><![CDATA[Infectious/Emerging Diseases]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<category><![CDATA[Pulmonary/Respiratory Medicine]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Virology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/advantages-of-intranasal-vaccination-against-sars-cov-2/</guid>

					<description><![CDATA[Intranasal vaccination is needle-free and elicits immunity at the site of infection, the respiratory tract Credit: UAB BIRMINGHAM, Ala. &#8211; There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/advantages-of-intranasal-vaccination-against-sars-cov-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">174491</post-id>	</item>
		<item>
		<title>Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma</title>
		<link>https://bioengineer.org/phase-two-cd19-antibody-drug-conjugate-trial-demonstrates-promise-for-aggressive-lymphoma/</link>
					<comments>https://bioengineer.org/phase-two-cd19-antibody-drug-conjugate-trial-demonstrates-promise-for-aggressive-lymphoma/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jul 2021 14:33:21 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<guid isPermaLink="false">https://bioengineer.org/phase-two-cd19-antibody-drug-conjugate-trial-demonstrates-promise-for-aggressive-lymphoma/</guid>

					<description><![CDATA[MUSC Hollings Cancer Center part of promising clinical trial for aggressive lymphoma Credit: MUSC Hollings Emma C. Vought MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The results of [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/phase-two-cd19-antibody-drug-conjugate-trial-demonstrates-promise-for-aggressive-lymphoma/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">174461</post-id>	</item>
		<item>
		<title>Geneticists reveal how mutation causes childhood cancer; use drug to reverse its effects</title>
		<link>https://bioengineer.org/geneticists-reveal-how-mutation-causes-childhood-cancer-use-drug-to-reverse-its-effects/</link>
					<comments>https://bioengineer.org/geneticists-reveal-how-mutation-causes-childhood-cancer-use-drug-to-reverse-its-effects/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 22 Jul 2021 15:44:45 +0000</pubDate>
				<category><![CDATA[Chemistry]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Genes]]></category>
		<category><![CDATA[Genetics]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<category><![CDATA[Pharmaceutical Science]]></category>
		<category><![CDATA[Pharmaceutical Sciences]]></category>
		<guid isPermaLink="false">https://bioengineer.org/geneticists-reveal-how-mutation-causes-childhood-cancer-use-drug-to-reverse-its-effects/</guid>

					<description><![CDATA[Credit: Trinity College Dublin. Geneticists from Trinity College Dublin have discovered how a specific genetic mutation called H3K27M causes a devastating, incurable childhood cancer, known as diffuse midline glioma (DMG), and &#8211; in lab studies working with model cell types &#8211; successfully reverse its effects to slow cancer cell growth with a targeted drug. Their [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/geneticists-reveal-how-mutation-causes-childhood-cancer-use-drug-to-reverse-its-effects/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">174370</post-id>	</item>
		<item>
		<title>New scoring system for assessing wound healing</title>
		<link>https://bioengineer.org/new-scoring-system-for-assessing-wound-healing/</link>
					<comments>https://bioengineer.org/new-scoring-system-for-assessing-wound-healing/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 21 Jul 2021 16:18:05 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[Cell Biology]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-scoring-system-for-assessing-wound-healing/</guid>

					<description><![CDATA[Credit: Mary Ann Liebert, Inc., publishers New Rochelle, NY, July 21, 2021&#8211; Evaluating the efficacy of novel therapies requires the ability to monitor wound progression accurately and reproducibly over time. Researchers have proposed a new scoring system for wound healing in mice based on parameters in each phase of healing, as described in an article [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/new-scoring-system-for-assessing-wound-healing/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">174276</post-id>	</item>
		<item>
		<title>Novel method predicts if COVID-19 clinical trials will fail or succeed</title>
		<link>https://bioengineer.org/novel-method-predicts-if-covid-19-clinical-trials-will-fail-or-succeed/</link>
					<comments>https://bioengineer.org/novel-method-predicts-if-covid-19-clinical-trials-will-fail-or-succeed/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 21 Jul 2021 13:42:40 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Algorithms/Models]]></category>
		<category><![CDATA[Business/Economics]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Computer Science]]></category>
		<category><![CDATA[Infectious/Emerging Diseases]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<category><![CDATA[Research/Development]]></category>
		<category><![CDATA[Technology/Engineering/Computer Science]]></category>
		<guid isPermaLink="false">https://bioengineer.org/novel-method-predicts-if-covid-19-clinical-trials-will-fail-or-succeed/</guid>

					<description><![CDATA[Researchers first to model COVID-19 completion vs. cessation study using machine learning Credit: Florida Atlantic University/College of Engineering and Computer Science In order to win the battle against COVID-19, studies to develop vaccines, drugs, devices and re-purposed drugs are urgently needed. Randomized clinical trials are used to provide evidence of safety and efficacy as well [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/novel-method-predicts-if-covid-19-clinical-trials-will-fail-or-succeed/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">174220</post-id>	</item>
		<item>
		<title>FDA approves Octapharma&#8217;s Octagam® 10% for adult dermatomyositis</title>
		<link>https://bioengineer.org/fda-approves-octapharmas-octagam-10-for-adult-dermatomyositis/</link>
					<comments>https://bioengineer.org/fda-approves-octapharmas-octagam-10-for-adult-dermatomyositis/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jul 2021 17:40:09 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Critical Care/Emergency Medicine]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Immunology/Allergies/Asthma]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<category><![CDATA[Orthopedic Medicine]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Pulmonary/Respiratory Medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/fda-approves-octapharmas-octagam-10-for-adult-dermatomyositis/</guid>

					<description><![CDATA[FDA approval based on positive results of international, multi-center ProDERM study Credit: Octapharma PARAMUS, N.J. &#8211; The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/fda-approves-octapharmas-octagam-10-for-adult-dermatomyositis/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">174164</post-id>	</item>
		<item>
		<title>Virginia Tech scientists uncover how a molecule improves appearance of surgery scars</title>
		<link>https://bioengineer.org/virginia-tech-scientists-uncover-how-a-molecule-improves-appearance-of-surgery-scars/</link>
					<comments>https://bioengineer.org/virginia-tech-scientists-uncover-how-a-molecule-improves-appearance-of-surgery-scars/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jul 2021 16:19:49 +0000</pubDate>
				<category><![CDATA[Biology]]></category>
		<category><![CDATA[Biomedical/Environmental/Chemical Engineering]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Cell Biology]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<category><![CDATA[Rehabilitation/Prosthetics/Plastic Surgery]]></category>
		<guid isPermaLink="false">https://bioengineer.org/virginia-tech-scientists-uncover-how-a-molecule-improves-appearance-of-surgery-scars/</guid>

					<description><![CDATA[Researchers find clues about how molecule improves appearance of scars Credit: (Gourdie Lab /Virginia Tech) Surgical scars treated with a molecule called alphaCT1 showed a long-term improvement in appearance when compared to control scars, according to multicenter, controlled Phase II clinical trials &#8211; a finding that could help surgeons improve patient outcomes. Now, a public-private [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/virginia-tech-scientists-uncover-how-a-molecule-improves-appearance-of-surgery-scars/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">174138</post-id>	</item>
		<item>
		<title>CNIO researchers clarify the role of the two isoforms of KRAS, the most common oncogene in humans</title>
		<link>https://bioengineer.org/cnio-researchers-clarify-the-role-of-the-two-isoforms-of-kras-the-most-common-oncogene-in-humans/</link>
					<comments>https://bioengineer.org/cnio-researchers-clarify-the-role-of-the-two-isoforms-of-kras-the-most-common-oncogene-in-humans/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jul 2021 19:49:42 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Biology]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cell Biology]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Disease in the Developing World]]></category>
		<category><![CDATA[Genes]]></category>
		<category><![CDATA[Genetics]]></category>
		<category><![CDATA[Health Professionals]]></category>
		<category><![CDATA[Molecular Biology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cnio-researchers-clarify-the-role-of-the-two-isoforms-of-kras-the-most-common-oncogene-in-humans/</guid>

					<description><![CDATA[These findings suggest that for therapies to be effective, they must be targeted at both gene products Credit: CNIO KRAS was one of the first oncogenes to be identified, a few decades ago. It is among the most common drivers of cancer and its mutations can be detected in around 25 per cent of human [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/cnio-researchers-clarify-the-role-of-the-two-isoforms-of-kras-the-most-common-oncogene-in-humans/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">174086</post-id>	</item>
		<item>
		<title>Personalized immunotherapy response studied in body-on-a-chip cancer models</title>
		<link>https://bioengineer.org/personalized-immunotherapy-response-studied-in-body-on-a-chip-cancer-models/</link>
					<comments>https://bioengineer.org/personalized-immunotherapy-response-studied-in-body-on-a-chip-cancer-models/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jul 2021 12:47:14 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<guid isPermaLink="false">https://bioengineer.org/personalized-immunotherapy-response-studied-in-body-on-a-chip-cancer-models/</guid>

					<description><![CDATA[Credit: WFIRM WINSTON-SALEM, NC, JULY 19, 2021 &#8212; Wake Forest researchers and clinicians are using patient-specific tumor &#8216;organoid&#8217; models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people. Immunotherapies, also known as biologic therapies, activate the body&#8217;s own immune system [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/personalized-immunotherapy-response-studied-in-body-on-a-chip-cancer-models/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">173997</post-id>	</item>
		<item>
		<title>On the front lines: Correctional nurses and the COVID-19 pandemic</title>
		<link>https://bioengineer.org/on-the-front-lines-correctional-nurses-and-the-covid-19-pandemic/</link>
					<comments>https://bioengineer.org/on-the-front-lines-correctional-nurses-and-the-covid-19-pandemic/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 15 Jul 2021 15:50:39 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Critical Care/Emergency Medicine]]></category>
		<category><![CDATA[Health Care Systems/Services]]></category>
		<category><![CDATA[Health Professionals]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<category><![CDATA[Public Health]]></category>
		<category><![CDATA[Stress/Anxiety]]></category>
		<guid isPermaLink="false">https://bioengineer.org/on-the-front-lines-correctional-nurses-and-the-covid-19-pandemic/</guid>

					<description><![CDATA[Credit: Mary Ann Liebert, Inc., publishers New Rochelle, NY, July 14, 2021-Firsthand reports from nurses in correctional facilities detail the challenges they faced during the COVID-19 pandemic. These firsthand accounts are reported in a special issue on correctional nursing in the Journal of Correctional Health Care. Click here (https://www.liebertpub.com/toc/jchc/27/2) to read the issue now. Karen [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/on-the-front-lines-correctional-nurses-and-the-covid-19-pandemic/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">173855</post-id>	</item>
		<item>
		<title>Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development</title>
		<link>https://bioengineer.org/launch-of-unite4tb-partnership-marks-a-new-era-in-tuberculosis-treatment-development/</link>
					<comments>https://bioengineer.org/launch-of-unite4tb-partnership-marks-a-new-era-in-tuberculosis-treatment-development/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 15 Jul 2021 15:43:33 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Infectious/Emerging Diseases]]></category>
		<category><![CDATA[Medical/Scientific Ethics]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<category><![CDATA[Pulmonary/Respiratory Medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/launch-of-unite4tb-partnership-marks-a-new-era-in-tuberculosis-treatment-development/</guid>

					<description><![CDATA[The partnership will accelerate the development of new Tuberculosis (TB) drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research &#038; Development Consortium Credit: UNITE4TB To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions for TB patients worldwide, a new consortium of 30 partners [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/launch-of-unite4tb-partnership-marks-a-new-era-in-tuberculosis-treatment-development/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">173853</post-id>	</item>
		<item>
		<title>Personalised 3D printed knee implant could help thousands of arthritis sufferers</title>
		<link>https://bioengineer.org/personalised-3d-printed-knee-implant-could-help-thousands-of-arthritis-sufferers/</link>
					<comments>https://bioengineer.org/personalised-3d-printed-knee-implant-could-help-thousands-of-arthritis-sufferers/#respond</comments>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 14 Jul 2021 15:58:48 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Medicine/Health]]></category>
		<category><![CDATA[Orthopedic Medicine]]></category>
		<category><![CDATA[Surgery]]></category>
		<guid isPermaLink="false">https://bioengineer.org/personalised-3d-printed-knee-implant-could-help-thousands-of-arthritis-sufferers/</guid>

					<description><![CDATA[Credit: University of Bath Pioneering &#8216;printed metal&#8217; procedure to create bespoke treatment for early knee osteoarthritis set to be trialled in the UK following MHRA approval. World&#8217;s first 3D printed high tibial osteotomy (HTO) device and procedure developed at University of Bath given approval for UK trials Bespoke titanium alloy HTO implants that fit perfectly [&#8230;]]]></description>
		
					<wfw:commentRss>https://bioengineer.org/personalised-3d-printed-knee-implant-could-help-thousands-of-arthritis-sufferers/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">173763</post-id>	</item>
	</channel>
</rss>
